Harrow, Inc. $HROW Stock Position Reduced by Deutsche Bank AG

Deutsche Bank AG lessened its position in shares of Harrow, Inc. (NASDAQ:HROW) by 1.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 106,031 shares of the company’s stock after selling 2,033 shares during the period. Deutsche Bank AG owned about 0.29% of Harrow worth $2,820,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of HROW. Braidwell LP lifted its holdings in Harrow by 106.3% during the 4th quarter. Braidwell LP now owns 907,039 shares of the company’s stock worth $30,431,000 after buying an additional 467,401 shares during the last quarter. Two Sigma Investments LP lifted its holdings in Harrow by 483.2% during the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock worth $5,044,000 after buying an additional 124,574 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Harrow by 10,500.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 42,400 shares of the company’s stock worth $1,423,000 after purchasing an additional 42,000 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of Harrow by 6.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock worth $22,301,000 after purchasing an additional 41,896 shares during the last quarter. Finally, Royce & Associates LP lifted its holdings in shares of Harrow by 12.0% in the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock worth $8,701,000 after purchasing an additional 35,006 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Down 0.2%

Shares of HROW stock opened at $38.23 on Wednesday. Harrow, Inc. has a 1 year low of $20.85 and a 1 year high of $59.23. The stock has a market cap of $1.41 billion, a PE ratio of -152.92 and a beta of 0.41. The business’s fifty day moving average is $33.48 and its 200-day moving average is $28.98. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. The company had revenue of $63.74 million for the quarter, compared to analysts’ expectations of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. Equities analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Zacks Research raised Harrow from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. HC Wainwright raised their price target on Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, August 13th. BTIG Research raised their price target on Harrow from $62.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. Cantor Fitzgerald assumed coverage on Harrow in a report on Friday, July 11th. They issued an “overweight” rating and a $76.00 price target on the stock. Finally, William Blair assumed coverage on Harrow in a report on Tuesday, June 10th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat, Harrow has a consensus rating of “Buy” and a consensus target price of $64.67.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.